
Lp(a)-Lowering Pelacarsen Shows Huge Disconnect With Cardiovascular Outcomes
Lowering lipoprotein(a), or Lp(a), did not translate into better cardiovascular outcomes in a secondary prevention population, at least not with pelacarsen in the Lp(a) HORIZON trial. Among people with elevated lipoprotein(a...




























